HIGH-VOLUME · CHRONIC KIDNEY DISEASE
dexlansoprazole Side Effects
dexlansoprazole (also sold as Dexilant) is HIGH-VOLUME in this FAERS book #160 of 524 by FAERS report count. Signature opener: CHRONIC KIDNEY DISEASE - CHRONIC KIDNEY DISEASE leads at 16,100 reports (39.5% of the book).
Data updated 2026-05-15
- 40,790
- FAERS reports
FAERS voluntary reports, 2008 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
Among 40,790 FAERS reports for dexlansoprazole, CHRONIC KIDNEY DISEASE is the most-reported reaction (16,100). Volume band HIGH-VOLUME #160 of 524 by FAERS report count.
High-report extract for dexlansoprazole (Dexilant): 40,790 FAERS rows (2008-2025). Top named reactions: CHRONIC KIDNEY DISEASE, ACUTE KIDNEY INJURY, RENAL FAILURE. Outcome stamps DEATH-HEAVY · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2008–2025). Stamps CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
CHRONIC KIDNEY DISEASE leads 16,100 of 40,790 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (7,813 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (3,607 reports, 8.8%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 1,827 |
| CHRONIC KIDNEY DISEASE | 1,592 |
| RENAL FAILURE | 1,331 |
| ACUTE KIDNEY INJURY | 1,051 |
| END STAGE RENAL DISEASE | 990 |
| TUBULOINTERSTITIAL NEPHRITIS | 348 |
| RENAL INJURY | 324 |
| CONDITION AGGRAVATED | 170 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 169 |
| DYSPNOEA | 163 |
| SEPSIS | 162 |
| NAUSEA | 159 |
| ANAEMIA | 156 |
| ABDOMINAL PAIN | 153 |
| DIABETES MELLITUS | 150 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 145 |
| VOMITING | 145 |
| REBOUND ACID HYPERSECRETION | 142 |
| SOMNOLENCE | 142 |
Reactions in Hospitalization Reports
Hospitalization mid-share (6,956, 17.1%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| CHRONIC KIDNEY DISEASE | 945 |
| FATIGUE | 932 |
| ACUTE KIDNEY INJURY | 901 |
| NAUSEA | 796 |
| DYSPNOEA | 759 |
| RENAL FAILURE | 738 |
| HEADACHE | 702 |
| DIARRHOEA | 700 |
| PNEUMONIA | 693 |
| PAIN | 686 |
| ASTHENIA | 524 |
| ABDOMINAL PAIN | 494 |
| COUGH | 489 |
| VOMITING | 480 |
| END STAGE RENAL DISEASE | 472 |
| PYREXIA | 468 |
| DRUG HYPERSENSITIVITY | 465 |
| ARTHRALGIA | 446 |
How to read dexlansoprazole FAERS figures (CASELOAD · DEATH-HEAVY · HOSP-MID)
FAERS holds 40,790 voluntary reports linked to dexlansoprazole (Dexilant), 2008-2025. Death is listed on 3,607 (8.8%). Hospitalization appears on 6,956 (17.1%). Top co-reported indication: Product Used For Unknown Indication.
CASELOAD books overweight common drugs and loud reporting cultures; CHRONIC KIDNEY DISEASE is the page opener, not a per-patient risk.
Read with dexlansoprazole
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 40,954 FAERS cases (Δ 164 heavier vs dexlansoprazole); DEATH-MARKED · HOSP-MID · MALE-LED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 41,632 FAERS cases (Δ 842 heavier vs dexlansoprazole); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 39,831 FAERS cases (Δ 959 lighter vs dexlansoprazole); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 41,778 FAERS cases (Δ 988 heavier vs dexlansoprazole); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 53.3 pp vs dexlansoprazole's DEATH-HEAVY): CASELOAD · HOSP-MID.
dexlansoprazole stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload CASELOAD and the label guide.